Oppenheimer downgraded Nevro to Perform from Outperform without a price target following the Q4 report. The firm sees an “unclear path to material growth.” The analyst admits to being wrong on the timing of the firm’s upgrade last year and believes a “wait-and-see attitude is warranted” as a new CEO “tries to right the ship.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NVRO:
- Nevro Corp Enhances Board and Governance with New Director Appointment
- Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
- NVRO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Nevro price target lowered to $19 from $23 at Canaccord
- Nevro announces Carelon publication on new interventional pain management policy
